The clinical presentation of restenosis after bare metal stent implantation: behind a facade of benignity.
Contrary to common belief, bare metal in-stent restenosis (ISR) seems to be not a benign clinical entity. Thus,we believed that continued efforts are warranted to prevent bare metal ISR, including aggressive use of drug-eluting stent (DES) to decrease the incidence of acute coronary syndromes. However, despite improved outcomes with DES, bare metal stent (BMS) will continue to play a role for both clinical and economic reasons and we feel that there is still a future for BMS.